Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance is gradually stabilizing, and it is expected to return to a good growth trajectory in 2025 [1][5] - The life sciences segment is experiencing continuous innovation and growth, with new product categories accelerating [5] - The medical innovation segment is recovering, with strong growth in hospital automation and public health services [5] - The company has a clear advantage in its niche areas and is actively expanding new business lines, with new orders growing rapidly [5] Financial Summary - Revenue for 2022 was 2,864.04 million, with a year-on-year growth of 34.72%. In 2023, revenue decreased to 2,280.90 million, a decline of 20.36%. It is projected to increase to 2,594.89 million in 2025, reflecting a growth of 13.62% [2] - Net profit attributable to the parent company was 600.79 million in 2022, down 28.90% year-on-year. It is expected to recover to 408.08 million in 2025, with a growth of 11.31% [2] - The gross margin for 2024 is projected to be 47.99%, with a slight decline from previous years [2] - The company’s earnings per share (EPS) for 2025 is expected to be 1.28 yuan, with a price-to-earnings (PE) ratio of 24.95 [2][5] Segment Performance - The life sciences segment generated revenue of 1,094 million in 2024, a year-on-year increase of 6.14%, driven by new product launches [5] - The medical innovation segment's revenue was 1,180 million in 2024, a decrease of 4.91%, but showing signs of recovery in automation and digital services [5] Future Projections - The company is expected to achieve net profits of 4.08 million, 4.83 million, and 5.64 million for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.28, 1.52, and 1.77 yuan [5][6]

Investment Rating - The report maintains a "Buy" rating for Haier Biomedical [6] Core Views - The company's operational resilience is highlighted, with revenue showing a quarter-on-quarter improvement since the second half of 2024, while profit performance is impacted by changes in investment net income [2][3] - Non-storage new industries are experiencing robust growth, with a 21.25% year-on-year increase, and the company is embracing AI-driven digital transformation [3] - Domestic market advantages are being solidified, with a 4.75% year-on-year increase in domestic revenue, while overseas market disruptions have been largely mitigated [4] Financial Performance Summary - In 2024, Haier Biomedical achieved operating revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit attributable to shareholders decreased by 9.71% to 367 million yuan [1][5] - The company reported a gross margin of 47.99% in 2024, with a stable adjusted gross margin of 50.43% [2] - The investment net income for 2024 was 23.8 million yuan, down 71.34% year-on-year, affecting profit growth [2] Revenue and Profit Forecast - The forecast for operating revenue from 2025 to 2027 is 2.623 billion yuan, 3.023 billion yuan, and 3.479 billion yuan, representing year-on-year growth rates of 14.9%, 15.2%, and 15.1% respectively [4][5] - The projected net profit attributable to shareholders for the same period is 448 million yuan, 535 million yuan, and 649 million yuan, with growth rates of 22.1%, 19.5%, and 21.3% respectively [4][5]

Investment Rating - The report maintains a "Buy" rating for Haier Biomedical [6] Core Views - The company's operational resilience is highlighted, with revenue showing quarter-on-quarter improvement since the second half of 2024, while profit performance is impacted by changes in investment net income [2][3] - Non-storage new industries are experiencing robust growth, with a 21.25% year-on-year increase, and the company is embracing AI-driven digital transformation [3] - Domestic market advantages are being solidified, with a 4.75% year-on-year increase in domestic revenue, while overseas market disruptions have been largely mitigated [4] Financial Performance Summary - In 2024, Haier Biomedical achieved operating revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit attributable to shareholders decreased by 9.71% to 367 million yuan [1][5] - The company reported a gross margin of 47.99% in 2024, a decrease of 2.64 percentage points year-on-year, but adjusted gross margin remains stable at 50.43% [2] - The investment net income for 2024 was 23.8 million yuan, down 71.34% year-on-year, affecting profit growth [2] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 2.623 billion, 3.023 billion, and 3.479 billion yuan, representing year-on-year growth rates of 14.9%, 15.2%, and 15.1% respectively [4][5] - Net profit forecasts for the same period are 448 million, 535 million, and 649 million yuan, with growth rates of 22.1%, 19.5%, and 21.3% respectively [4][5]

Group 1 - The core viewpoint of the news is that Haier Bio has made significant progress in mergers and acquisitions, AI empowerment, and R&D investment in 2024, with a 50% increase in revenue from the merger industry [1] - Haier Bio's AI empowerment spans five industries, including the integration of vaccine appointment systems with DeepSeek and the construction of various product solutions for smart medication scenarios [1] - The company focuses its R&D investment on traditional advantageous fields, emerging industry development, and future industry layout, with approximately one-third of new users in the domestic market coming from county-level markets and key core user groups [1] Group 2 - The international market strategy involves a "one country, one policy" approach to enhance localization capabilities, emphasizing regional product planning and expanding new user scenarios [1] - Non-storage business is experiencing rapid growth overseas, with expectations for continued positive development [1] - Domestic orders are abundant, and overseas orders are rolling, with a business opportunity funnel exceeding 10 billion [1]

Investment Rating - The investment rating for the company is "Accumulate" [4] Core Views - The company reported a stable recovery in performance with a slight increase in revenue and a decrease in net profit for 2024. Revenue reached 2.284 billion yuan, a year-on-year increase of 0.13%, while net profit attributable to shareholders was 367 million yuan, a decline of 9.71% [1][2] - The company has shown a strong growth trajectory in new industries, with a 21.25% increase in revenue from new sectors, which now account for 45.47% of total revenue, reflecting a 7.93 percentage point increase year-on-year [2] - The life sciences segment generated 1.094 billion yuan in revenue, up 6.14% year-on-year, driven by automation and intelligent solutions in laboratory settings [3] - The medical innovation segment saw revenue of 1.180 billion yuan, a decline of 4.91%, but excluding the solar vaccine program, it showed positive growth [4] - Domestic revenue remained resilient with a 4.75% increase, while overseas revenue decreased by 8.73%, although it is expected to accelerate in 2025 [8] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 2.284 billion yuan, with a slight year-on-year growth of 0.1%. The net profit attributable to shareholders was 367 million yuan, down 9.7% from the previous year [1][10] - The gross margin for 2024 was 48.0%, a decrease of 2.64 percentage points, but if adjusted for accounting policy changes, it would be 50.43%, indicating stability [2] Business Segments - The life sciences segment's revenue reached 1.094 billion yuan, growing 6.14% year-on-year, focusing on automation and intelligent solutions [3] - The medical innovation segment generated 1.180 billion yuan, with a decline of 4.91%, but showed strong growth in hospital automation services [4] Market Outlook - The company anticipates revenue growth of 2.620 billion yuan in 2025, with a projected net profit of 446 million yuan, reflecting a year-on-year increase of 21.7% [9][10] - The overseas market is expected to see significant acceleration in 2025, with the company establishing localized teams in over 150 countries [8]

Core Viewpoint - The company reported its 2024 annual results, showing a slight revenue increase but a decline in net profit, with expectations for significant growth in overseas markets in 2025 [1][2]. Financial Performance - In 2024, the company achieved revenue of 2.28 billion yuan (+0.1%) and a net profit attributable to shareholders of 367 million yuan (-9.7%), with a non-recurring net profit of 321 million yuan (-2.9%) [1]. - Quarterly revenue for 2024 was 690 million yuan in Q1, 540 million yuan in Q2, 560 million yuan in Q3, and 500 million yuan in Q4, showing a quarterly growth of +0%, -8.1%, +0.5%, and +10.4% respectively [1]. - Quarterly net profit attributable to shareholders was 140 million yuan in Q1, 97 million yuan in Q2, 75 million yuan in Q3, and 57 million yuan in Q4, with changes of +0.1%, -31.4%, -5%, and +17.6% respectively [1]. Business Segments - The storage segment experienced negative growth, but excluding the solar vaccine cold storage, it remained flat; non-storage revenue grew by 21% [1]. - The low-temperature storage business faced challenges but showed improvement, with the decline primarily due to delays in solar vaccine orders. The second half of the year saw a narrowing decline, achieving positive growth in Q4 [2]. - Non-low-temperature storage equipment, including automated medication, laboratory consumables, and digital public health, continued to grow rapidly [2]. Market Expansion - The company is deepening its global presence, with overseas markets (excluding solar vaccine solutions) achieving double-digit growth. The company has established localized teams in key countries such as the USA, UK, Netherlands, Singapore, and India [2]. - The company has received local certification for 56 new product models, totaling over 400 overseas product certifications, and is accelerating local construction to shorten product delivery cycles [2]. Profit Forecast - The company forecasts net profit attributable to shareholders of 440 million yuan in 2025, 520 million yuan in 2026, and 600 million yuan in 2027, indicating steady growth and potential for future acquisitions [3].

Group 1 - The company announced a share repurchase plan with a total expected amount between 100 million and 200 million RMB [1][2] - The repurchase plan was approved on January 13, 2025, and will be implemented within 12 months [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of March 31, 2025, the company has repurchased a total of 524,614 shares, accounting for 0.1650% of the total share capital [1] - The total amount spent on repurchased shares is 17,467,616.72 RMB, with an average price range of 31.78 RMB to 34.69 RMB per share [1] - The company will continue to make repurchase decisions based on market conditions and will fulfill information disclosure obligations [2]

重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | --- | --- | | 回购方案实施期限 | 第三届董事会第四次会议审议通过后 12 个月 | | 预计回购金额 | 10,000 万元~20,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 524,614 股 | | 累计已回购股数占总股本比例 | 0.1650% | | 累计已回购金额 | 17,467,616.72 元 | | 实际回购价格区间 | 31.78 元/股~34.69 元/股 | 一、 回购股份的基本情况 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 1 月 13 日召 开第三届董事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》（以下简称"本次回购方案"），同意公司以自有资金通过上海证券 交易所股票交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购价格 不 ...

Core Viewpoint - Haier Biomedical's stock closed at 34.58 yuan, down 2.40%, with a rolling PE ratio of 29.99 times and a total market capitalization of 10.995 billion yuan [1] Group 1: Company Overview - Haier Biomedical focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, through two main segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health [2] - Key products include low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Group 2: Financial Performance - In the latest annual report for 2024, the company achieved operating revenue of 2.284 billion yuan, a year-on-year increase of 0.13%, and a net profit of 367 million yuan, a year-on-year decrease of 9.71% [3] - The sales gross margin stood at 47.99% [3] Group 3: Market Position - The average PE ratio for the medical device industry is 44.72 times, with a median of 32.59 times, placing Haier Biomedical at the 69th position in the industry [1][3] - As of February 28, 2025, the number of shareholders increased to 13,246, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1]

公募基金方面本期较上一季度持股减少的公募基金共计1个，即华宝中证医疗ETF，持股减少占比小幅 下跌。本期较上一季度新披露的公募基金共计35个，主要包括科创100ETF基金、科创100、鹏华优质治 理混合(LOF)A、医疗器械ETF、中信保诚精萃成长混合A等。本期较上一季未再披露的公募基金共计7 个，主要包括广发安润一年持有期混合A、广发集远债券A、国泰君安创新医药混合发起A、汇添富中 证互联网医疗指数(LOF)A、国泰君安品质生活混合发起A等。 2025年3月29日，海尔生物(688139.SH)发布2024年年度报告。截至2025年3月28日，共有56个机构投资 者披露持有海尔生物A股股份，合计持股量达2.03亿股，占海尔生物总股本的63.76%。其中，前十大机 构投资者包括青岛海尔生物医疗控股有限公司、青岛海智汇赢股权投资管理有限公司-青岛海创睿股权 投资基金中心(有限合伙)、天津海盈康企业管理合伙企业(有限合伙)、天津海创盈康企业管理合伙企业 (有限合伙)、香港中央结算有限公司、青岛久实投资管理有限公司-久实优选1号私募证券投资基金、施 罗德投资管理(香港)有限公司-施罗德环球基金系列中国A股(交易所) ...